Weighted Average Number of Shares Outstanding, Diluted of BriaCell Therapeutics Corp. from 31 Jan 2022 to 31 Jan 2026

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
BriaCell Therapeutics Corp. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Jan 2022 to 31 Jan 2026.
  • BriaCell Therapeutics Corp. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Jan 2026 was 2,802,337, a 938% increase year-over-year.
  • BriaCell Therapeutics Corp. annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 423,114, a 286% increase from 2024.
  • BriaCell Therapeutics Corp. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 109,699, a 99% decline from 2023.
  • BriaCell Therapeutics Corp. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 15,619,676, a 0.81% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

BriaCell Therapeutics Corp. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 2,802,337 +2,532,380 +938% 01 Nov 2025 31 Jan 2026 10-Q 10 Mar 2026 2026 Q2
Q3 2025 1,883,906 +1,706,300 +961% 01 Aug 2025 31 Oct 2025 10-Q 11 Dec 2025 2026 Q1
Q2 2025 423,114 +313,415 +286% 01 May 2025 31 Jul 2025 10-K 16 Oct 2025 2025 FY
Q1 2025 3,735,517 +2,670,069 +251% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q3
Q4 2024 269,957 -795,491 -75% 01 Nov 2024 31 Jan 2025 10-Q 10 Mar 2026 2026 Q2
Q3 2024 177,606 -16,497,285 -99% 01 Aug 2024 31 Oct 2024 10-Q 11 Dec 2025 2026 Q1
Q2 2024 109,699 -15,509,977 -99% 01 May 2024 31 Jul 2024 10-K 16 Oct 2025 2025 FY
Q1 2024 1,065,448 -14,452,624 -93% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q3
Q4 2023 1,065,448 -14,452,570 -93% 01 Nov 2023 31 Jan 2024 10-Q 12 Mar 2025 2025 Q2
Q3 2023 16,674,891 +1,156,873 +7.5% 01 Aug 2023 31 Oct 2023 10-Q 16 Dec 2024 2025 Q1
Q2 2023 15,619,676 01 May 2023 31 Jul 2023 10-K 29 Oct 2024 2024 FY
Q1 2023 15,518,072 +159,125 +1% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q3
Q4 2022 15,518,018 -2,887,596 -16% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q2
Q3 2022 15,518,018 01 Aug 2022 31 Oct 2022 10-Q 14 Dec 2023 2024 Q1
Q1 2022 15,358,947 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023 2023 Q3
Q4 2021 18,405,614 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023 2023 Q2

BriaCell Therapeutics Corp. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 423,114 +313,415 +286% 01 Aug 2024 31 Jul 2025 10-K 16 Oct 2025 2025 FY
2024 109,699 -15,509,977 -99% 01 Aug 2023 31 Jul 2024 10-K 16 Oct 2025 2025 FY
2023 15,619,676 +125,585 +0.81% 01 Aug 2022 31 Jul 2023 10-K 29 Oct 2024 2024 FY
2022 15,494,091 01 Aug 2021 31 Jul 2022 10-K 25 Oct 2023 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.